Exchange: NASDAQ·Updated 08:07 PM EDT

PCVX News

News
all
press releases
Moderna, Vaxcyte and Novavax Are Trending After-Hours as Suspected Pneumonic Plague In Russia Stirs Anxiety
Vaccine stocks are trending on Tuesday. Shares of Moderna Inc. (NASDAQ:MRNA), Vaxcyte Inc. (NASDAQ:PCVX) and Novavax Inc. (NASDAQ:NVAX) are moving in the after-hours session on Monday. Moderna rose 0.17% toread more...
Benzinga
Moderna, Vaxcyte and Novavax Are Trending After-Hours as Suspected Pneumonic Plague In Russia Stirs Anxiety
Vaccine stocks are trending on Tuesday. Shares of Moderna Inc. (NASDAQ:MRNA), Vaxcyte Inc. (NASDAQ:PCVX) and Novavax Inc. (NASDAQ:NVAX) are moving in the after-hours session on Monday. Moderna rose 0.17% toread more...
Benzinga
More News
NVAX Stock Outruns Moderna As Vaxcyte’s Shot Clears A Late-Stage Test
Vaxcyte said earlier on Monday that its experimental pneumonia vaccine, VAX-31, met the main goals of a late-stage study in adults 50 and older.
Stocktwits
PCVX Stock Hits Fresh 52-Week High On Late-Stage Win In Adult Pneumonia Vaccine Race: Jefferies Says It Hit ‘Blue-Sky’ Case
In the OPUS-1 study, Vaxcyte’s VAX-31 matched or beat immune responses from Pfizer’s Prevnar 20 and Merck’s Capvaxive on most strains those vaccines cover.
Stocktwits
Stocks making the biggest moves midday: Microsoft, SpaceX, Vaxcyte, Banco Bradesco, DraftKings & more
Here are some of the companies making headlines in midday trading...
CNBC: Top News
RXO, Vaxcyte, PTC And Other Big Stocks Moving Higher On Monday
U.S. stocks mixed as Dow falls 250+ points; RXO surges 23% on $5.8B C.H. Robinson deal, while Vaxcyte and PTC post major gains.read more...
Benzinga
Vaxcyte Stock Hits New 52-Week High - Here's Why
Vaxcyte announced positive Phase 3 OPUS-1 trial results for its VAX-31 vaccine candidate, setting the stage for an FDA BLA filing.read more...
Benzinga
Vaxcyte’s VAX-31 Clears Major Phase 3 Hurdle
Vaxcyte (NASDAQ:PCVX) delivered the kind of pivotal clinical readout that can fundamentally reshape a biotech investment story: its 31-valent pneumococcal vaccine candidate, VAX-31, met all prespecified primary endpoints in the pivotal OPUS-1 Phase 3 trial.
24-7 Market News
Vaxcyte's VAX-31 Meets Key Phase 3 Goals Against Prevnar 20 And Capvaxive; Stock Up
(RTTNews) - Monay, Vacyte (PCVX) reported positive topline results from its pivotal Phase 3 OPUS-1 trial, with VAX-31 meeting all prespecificed primary endpoints in adults...
Nasdaq News: Markets
Notable Friday Option Activity: PCVX, RDDT, CBT
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Vaxcyte Inc (Symbol: PCVX), where a total of 18,106 contracts have traded so far, representing approximately 1.8 million underlying shares. That amounts to about 128.2...
Nasdaq News: Markets
Alphabet To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Monday
Analysts raised targets for Vertex and Okta, while cutting targets for McDonald's, AutoZone, Vaxcyte and Camping World.read more...
Benzinga

Advertisement|Remove ads.